

ASX ANNOUNCEMENT

17 December 2024

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 16 December 2024 (US time), Anteris Technologies Global Corp. (NASDAQ: AVR; ASX: AVR) (**Anteris** or the **Company**) issued 14,800,000 shares of Common Stock (**Shares**) to investors in the Company's U.S. initial public offering.

Anteris gives notice under section 708(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**)¹, that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this Notice, the Company has complied with:
 - (a) section 601CK of the Corporations Act; and
 - (b) sections 674 and 674A of the Corporations Act; and
3. as at the date of this Notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

¹ As modified by ASIC Class Order 14/827 and ASIC Instrument 24-0923.

REGISTERED OFFICE

Toowong Tower, Level 3, Suite 302
9 Sherwood Road
Toowong, QLD 4066
Australia



BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

T: +61 1300 550 310
info.au@anteristech.com
anteristech.com

For personal use only

About Anteris Technologies Global Corp. (ASX: AVR)

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR[®] Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

DurAVR[®] THV is made using a single piece of molded ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Authorisation and Additional information

This announcement was authorised by the Board of Directors of Anteris Technologies Global Corp.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech

